Kuramochi-style 6-type Combined Immunotherapy: Comprehensive Reconstruction of the Immune Defense Line
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
Developed by Dr. Tsuneo Kuramochi (deceased) in Japan, the "6-type Combined Immunotherapy" is a next-generation cellular therapy. Unlike traditional treatments that target only a single cell type (such as NK cells alone or dendritic cells alone), this technology simultaneously activates and massively proliferates six key types of immune effector cells within the human body.
Core Technology: Combined Culture of Six Cell Types
Under strictly controlled laboratory conditions, this therapy expands the following cells from tens of millions to 2 to 5 billion cells:
- γδ T cells: Possess powerful innate anti-cancer capabilities.
- NK cells (Natural Killer cells): Instantly detect and eliminate mutated cells.
- NKT cells: Combine characteristics of both T and NK cells; they are resilient to chemotherapy and radiotherapy.
- Cytotoxic T Lymphocytes (CTL): Execute precision strikes after receiving cues from dendritic cells.
- Dendritic Cells (DC): The commanders of the immune system, receiving WT1 antigen prompts to precisely identify cancer cells.
- Helper T cells: Secret cytokines to regulate and strengthen the overall immune response.
Treatment Overview
- Patent: The simultaneous activation technique is patented in Japan and South Korea. A patent concerns the technique itself and does not indicate therapeutic effect.
- Scope of use: The clinic considers it for many solid tumors, excluding certain leukemias and malignant lymphomas. Whether it is suitable for an individual patient is decided by a physician.
- Burden and side effects: The treatment uses the patient's own cells and is given as an outpatient infusion, so hospitalization is generally not required. Side effects and physical burden vary by individual; please confirm with the physician.
- Use with standard treatment: Whether this therapy is used alongside standard chemotherapy or radiotherapy is determined by a physician. Some studies in the literature have examined such combinations, but their effect has not been established.
- Research observations in the literature: The therapy is also used after surgery in some cases. Whether it prevents recurrence or metastasis has not been established; findings on this point remain at the level of research observations.
Treatment Process
The treatment typically involves blood collection followed by intravenous infusion. The cell culture cycle takes approximately three weeks. As an outpatient treatment, patients can maintain their normal daily routines without altering their social or professional schedules.
About Senshin (Advanced) Clinic
This therapy is administered at "Senshin Clinics" located in cities such as Fukuoka and Tokyo. The medical team is led by current director Dr. Toshihide Aso; whether the treatment is suitable is assessed individually by the clinic's physicians.
[Medical Supporter Compliance Statement] Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.